Thursday, October 13, 2022
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by up to 640,000-plus square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit https://investors.item9labscorp.com/.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
A Purchase Agreement. On Tuesday, Item 9 Labs announced a Purchase Agreement with ClearThink Capital Partners, LLC dated September 8, 2022 for ClearThink to purchase up to $25 million in a Equity Line of Credit. Alongside the agreement, the Company agreed to issue ClearThink 400,000 restricted shares of the Company’s Common Stock as a “Commitment Fee Shares.”
Other Agreements. The Purchase Agreement brought along two other agreements: a Registration Rights Agreement and a Securities Purchase Agreement. The Registration Rights Agreement lets Item 9 Labs file a registration statement with the SEC covering the common stock shares being issued under the Purchase Agreement and the Securities Purchase Agreement is the additional purchase of 266,666 shares of restricted common stock for a price of $200,000.
Get the Full Report
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.